AKTX — Akari Therapeutics Share Price
0.000.00%
Last trade - 00:00- $14.45m
- $15.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.61% | ||
| Return on Equity | -179.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 4,193 | 11,231 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Directors
- Ray Prudo CHM (76)
- Clive Richardson CEO (56)
- Torsten Hombeck CFO (51)
- Michael Grissinger DRC (67)
- David Byrne IND (61)
- Peter Feldschreiber IND (77)
- James Hill IND (75)
- Stuart Ungar IND (77)
- Donald Williams IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 7th, 2004
- Public Since
- January 31st, 2014
- No. of Shareholders
- 415
- No. of Employees
- 8
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 24,289,231,523
- Address
- 22 BOSTON WHARF ROAD, FL 7, BOSTON, 02210
- Web
- https://www.akaritx.com/
- Phone
- +1 6463500702
- Auditors
- BDO USA, LLP
Upcoming Events for AKTX
Q2 2025 Akari Therapeutics PLC Earnings Release
Q3 2025 Akari Therapeutics PLC Earnings Release
Similar to AKTX
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the Akari Therapeutics share price?
As of Today at 19:09 UTC, shares in Akari Therapeutics are trading at $1.27. This share price information is delayed by 15 minutes.
How has the Akari Therapeutics share price performed this year?
Shares in Akari Therapeutics last closed at $1.27 and the price had moved by -14.19% over the past 365 days. In terms of relative price strength the Akari Therapeutics share price has underperformed the S&P500 Index by -23.62% over the past year.
What are the analyst and broker recommendations for Akari Therapeutics?
The overall consensus recommendation for Akari Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Akari Therapeutics dividend yield?
Akari Therapeutics does not currently pay a dividend.
Does Akari Therapeutics pay a dividend?
Akari Therapeutics does not currently pay a dividend.
When does Akari Therapeutics next pay dividends?
Akari Therapeutics does not currently pay a dividend.
How do I buy Akari Therapeutics shares?
To buy shares in Akari Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Akari Therapeutics?
As of the previous close price of $1.27, shares in Akari Therapeutics had a market capitalisation of $15.42m.
Where are Akari Therapeutics shares listed?
Here are the trading details for Akari Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AKTX
What kind of share is Akari Therapeutics?
Based on an overall assessment of its quality, value and momentum Akari Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Akari Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Akari Therapeutics is $80.00. That is 6199.21% above the last closing price of $1.27.
Analysts covering Akari Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.60 for the next financial year.
Find out moreWhat is the trend in the Akari Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akari Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -39.61%.
As of the last closing price of $1.27, shares in Akari Therapeutics were trading -33.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Akari Therapeutics PE Ratio?
The Akari Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Akari Therapeutics?
Akari Therapeutics' management team is headed by:
- Ray Prudo - CHM
- Clive Richardson - CEO
- Torsten Hombeck - CFO
- Michael Grissinger - DRC
- David Byrne - IND
- Peter Feldschreiber - IND
- James Hill - IND
- Stuart Ungar - IND
- Donald Williams - IND